{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:33:45Z","timestamp":1791876825234,"version":"4.3.4"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The mode of death in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) remains poorly understood and may vary by EF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the mode of death according to EF and the treatment effect of finerenone on cause-specific mortality in patients with HFmrEF\/HFpEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a prespecified secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial, which evaluated clinical outcomes in 6001 patients with HF and EF greater than or equal to 40% randomly assigned to finerenone or placebo. The mode of death in relation to baseline EF categories (&amp;amp;lt;50%, \u226550-&amp;amp;lt;60%, and \u226560%) was examined, and the effect of randomized treatment on cause-specific death in Cox regression models was assessed. Data analysis was conducted between September 2024 and January 2025.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Finerenone vs placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Mode of death as centrally adjudicated by a clinical end points committee.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1013 patients (16.9%; median [IQR] age, 76 [69-82] years; 594 male [58.6%]) who died during median (IQR) follow-up of 32 (23-36) months, mode of death was ascribed to cardiovascular causes in 502 (49.6%), noncardiovascular causes in 368 (36.3%), and undetermined cause in 143 (14.1%). Of cardiovascular deaths, 215 (42.8%) were due to sudden death, 163 (32.4%) to HF, 48 (9.6%) to stroke, 25 (5.0%) to myocardial infarction, and 51 (10.2%) to other cardiovascular causes. The proportion of all-cause, cardiovascular, and sudden death was higher in those with EF less than 50%. The proportion of deaths related to HF was similar across EF categories, and the proportion of deaths due to myocardial infarction, stroke, and other cardiovascular causes was low regardless of EF. Randomization to finerenone did not significantly reduce death or cause-specific death compared with placebo in any EF category.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among patients with HFmrEF\/HFpEF in the FINEARTS-HF randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with EF less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04435626\">NCT04435626<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.0860","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T10:31:45Z","timestamp":1743330705000},"page":"678","source":"Crossref","is-referenced-by-count":12,"title":["Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction"],"prefix":"10.1001","volume":"10","author":[{"given":"Akshay S.","family":"Desai","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Pabon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"University of Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaviana","family":"Amarante","sequence":"additional","affiliation":[{"name":"Bayer, Cardiology and Nephrology Clinical Development, Bayer SA, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer plc, Research & Development, Pharmaceuticals, Reading, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Scheerer","sequence":"additional","affiliation":[{"name":"Bayer AG, Global Medical Affairs, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lage","sequence":"additional","affiliation":[{"name":"Bayer, Cardiology and Nephrology Clinical Development, Bayer SA, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hoi250016r1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","article-title":"Mode of death in heart failure with preserved ejection fraction.","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"hoi250016r2","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","article-title":"Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.","volume":"110","author":"Solomon","year":"2004","journal-title":"Circulation"},{"issue":"12","key":"hoi250016r3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008597","article-title":"Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF trial.","volume":"14","author":"Desai","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"12","key":"hoi250016r4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","article-title":"Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER.","volume":"7","author":"Desai","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10456","key":"hoi250016r5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide vs placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"hoi250016r6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamacardio.2023.5318","article-title":"Dapagliflozin and mode of death in heart failure with improved ejection fraction: a post hoc analysis of the DELIVER trial.","volume":"9","author":"Vardeny","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"16","key":"hoi250016r7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi250016r8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial.","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi250016r9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hoi250016r10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"hoi250016r11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jacc.2014.06.1199","article-title":"Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure.","volume":"64","author":"Greene","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi250016r12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ejhf.1058","article-title":"What have we learned about heart failure with midrange ejection fraction 1 year after its introduction?","volume":"19","author":"Nauta","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"hoi250016r13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction.","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"10458","key":"hoi250016r14","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"issue":"22","key":"hoi250016r15","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.jacc.2024.08.033","article-title":"Why Have we not been able to demonstrate reduced mortality in patients with HFmrEF\/HFpEF?","volume":"84","author":"Kondo","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"hoi250016r16","unstructured":"A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF). ClinicalTrials.gov identifier: NCT06008197. Updated March 1, 2024. Accessed March 13, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06008197"},{"key":"hoi250016r17","unstructured":"A study to evaluate finerenone on clinical efficacy and safety in patients with heart failure who are intolerant or not eligible for treatment with steroidal mineralocorticoid receptor antagonists (FINALITY-HF). ClinicalTrials.gov identifier: NCT06033950. Updated March 11, 2025. Accessed March 13, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06033950"},{"key":"hoi250016r18","unstructured":"A study to determine the efficacy and safety of finerenone and SGLT2i in combination in hospitalized patients with heart failure (CONFIRMATION-HF). ClinicalTrials.gov identifier: NCT06024746. Updated March 11, 2025. Accessed March 13, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06024746"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2832033\/jamacardiology_desai_2025_oi_250016_1750865901.48146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:01:01Z","timestamp":1752073261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2832033"}},"subtitle":["The FINEARTS-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.0860","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}